L575-0256 Screening compound: N-{3-[methyl(phenyl)amino]propyl}-4-[1-methyl-3-(pyrrolidine-1-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-4-oxobutanamide

L575-0256 Screening compound: N-{3-[methyl(phenyl)amino]propyl}-4-[1-methyl-3-(pyrrolidine-1-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-4-oxobutanamide
L575-0256 Screening compound: N-{3-[methyl(phenyl)amino]propyl}-4-[1-methyl-3-(pyrrolidine-1-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-4-oxobutanamide alternative view

Chemical Structure Depiction of ChemDiv screening compound L575-0256
N-{3-[methyl(phenyl)amino]propyl}-4-[1-methyl-3-(pyrrolidine-1-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-4-oxobutanamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

L575-0256

Molecular Formula

C26H36N6O3 (C26 H36 N6 O3)

Compound Name

N-{3-[methyl(phenyl)amino]propyl}-4-[1-methyl-3-(pyrrolidine-1-carbonyl)-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl]-4-oxobutanamide

IUPAC name

N-{3-[methyl(phenyl)amino]propyl}-4-[1-methyl-3-(pyrrolidine-1-carbonyl)-1H4H5H6H7H-pyrazolo[43-c]pyridin-5-yl]-4-oxobutanamide

SMILES

CN(CCCNC(CCC(N(CC1)Cc2c1n(C)nc2C(N1CCCC1)=O)=O)=O)c1ccccc1

InChI

InChI=1S/C26H36N6O3/c1-29(20-9-4-3-5-10-20)15-8-14-27-23(33)11-12-24(34)32-18-13-22-21(19-32)25(28-30(22)2)26(35)31-16-6-7-17-31/h3-5,9-10H,6-8,11-19H2,1-2H3,(H,27,33)

InChI Key

YVHHZVROJUJBJL-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD27463505

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

480.61

Hydrogen Bond Acceptors Count

7.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

12.00

Number of Nitrogen and Oxygen Atoms

9

Partition Coefficient, logP

0.065

Distribution Coefficient, logD

0.059

Water Solubility, LogSw

-1.81

Polar Surface Area

75.571

Acid Dissociation Constant (pKa)

14.88

Base Dissociation Constant (pKb)

5.52

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

53.80

L575-0256 in Drug Discovery

Included in Screening Libraries

Anticancer Library (62698 compounds)

Cysteine Proteases Inhibitors Library (7839 compounds)

GPCR Targeted Library (31838 compounds)

Hsp90-Targeted Library (11355 compounds)

PPI Inhibitors Tripeptide Mimetics (23972 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Cancer
  • Infections
  • Cancer
  • Musculoskeletal
  • Digestive system
  • Nervous system
  • Cardiovascular
  • Skin
  • Metabolic
  • Endocrine
  • Immune system
  • Musculoskeletal
  • Respiratory tract
  • Nervous system
  • Congenital
  • Skin
  • Metabolic
  • Endocrine
  • Cancer
  • Digestive system
  • Respiratory tract
  • Male
  • Female
  • Hemic and lymphatic
  • Immune system
Targets:
  • Proteases
  • GPCR
Mechanism of action:
  • Receptor's ligands
  • PPI modulators
Structure:
  • Mimetics

References: we are preparing a list of scientific research reports with L575-0256 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound L575-0256?
Check Price and Availability of L575-0256, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of L575-0256 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for L575-0256
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for L575-0256
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of L575-0256 available by request